Merck (MRK) is back in focus after MSD Animal Health received European Commission marketing authorization for NOBIVAC NXT HCPChFeLV, a combination feline vaccine that uses RNA particle technology and targets five significant feline pathogens.

Merck’s latest product and access announcements come as the stock trades at $130.20, with a 90 day share price return of 16.08% and a 1 year total shareholder return of 69.70%, suggesting momentum has recently been strong.

If you are looking beyond large pharma, this is a good moment to see what is happening in smaller high growth areas using the 41 healthcare AI stocks

After such a strong run in Merck’s share price, the stock now sits close to some analyst targets but well below one intrinsic value estimate. So where does fair value really sit in that spread?

Most Popular Narrative: 2% Undervalued

Merck is trading at $130.20 against a widely followed fair value estimate of $132.78, which puts the stock slightly below that narrative anchor and keeps attention on what is baked into those long term assumptions.

With its acquisition and licensing strategy, Merck has nearly tripled its late-phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid-2030s, driving earnings growth.

Curious what sits behind that expanded pipeline story and fair value gap? The narrative leans on specific revenue trajectories, margin shifts and a future earnings multiple that might surprise you.

Result: Fair Value of $132.78 (UNDERVALUED)

However, Merck’s story can shift quickly if policy changes on drug pricing bite harder than expected, or if the post KEYTRUDA exclusivity period weighs more heavily on revenues.

Another View On Merck’s Valuation

The analyst narrative anchors Merck around a fair value of $132.78, which leaves the stock only slightly below that mark. Our DCF model tells a very different story. It points to a future cash flow value closer to $228.37, which presents Merck as significantly undervalued. Which version of “fair” seems more realistic to you?

Next Steps

Does the mix of enthusiasm and concern around Merck feel justified to you, or a little stretched either way? Use the key datapoints and valuation views to pressure test your own thesis, then weigh those against the 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Merck?

If Merck has sharpened your interest, do not stop here. Use these focused tools to spot other opportunities that could fit your goals before the crowd notices.

• Zero in on quality at a discount by scanning companies that appear mispriced relative to their fundamentals using the 55 high quality undervalued stocks
• Strengthen your income stream by hunting for companies with higher yields and resilient payouts using the 9 dividend fortresses
• Prioritise resilience by reviewing companies that carry lower overall risk scores using the 81 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.